Literature DB >> 15625031

Medical Therapy of Crohn's Disease.

Shamina Dhillon1, Edward V Loftus.   

Abstract

There is no medical or surgical treatment that provides a permanent cure for Crohn's disease (CD). However, an evolving understanding of the pathogenesis of CD has provided clinicians with a diversity of medical treatment options for the disease. The goal of therapy is to induce and maintain clinical remission. The efficacy of immune-modifying agents such as azathioprine/6-mercaptopurine and infliximab have supported a paradigm shift in CD treatment in which maintenance agents are introduced earlier in the disease course. At the same time, it is imperative to balance the efficacy, safety, and tolerability of medical therapy. Given the variable and relapsing clinical course of CD, the physician and patient should ideally develop an ongoing relationship that allows for individualization of treatment regimens, monitoring of response and side effects, and modification of the therapeutic strategy in the absence of improvement.

Entities:  

Year:  2005        PMID: 15625031     DOI: 10.1007/s11938-005-0048-2

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN: 1092-8472


  68 in total

1.  Methotrexate in Crohn's disease: results of a randomized, double-blind, placebo-controlled trial.

Authors:  S Arora; W Katkov; J Cooley; J A Kemp; D E Johnston; R H Schapiro; D Podolsky
Journal:  Hepatogastroenterology       Date:  1999 May-Jun

2.  Preliminary study of ciprofloxacin in active Crohn's disease.

Authors:  George L Arnold; Mary R Beaves; Vladimir O Pryjdun; William J Mook
Journal:  Inflamm Bowel Dis       Date:  2002-01       Impact factor: 5.325

Review 3.  Infliximab.

Authors:  E Valle; M Gross; S J Bickston
Journal:  Expert Opin Pharmacother       Date:  2001-06       Impact factor: 3.889

4.  Clinical patterns in Crohn's disease: a statistical study of 615 cases.

Authors:  R G Farmer; W A Hawk; R B Turnbull
Journal:  Gastroenterology       Date:  1975-04       Impact factor: 22.682

5.  Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences.

Authors:  Edward V Loftus
Journal:  Gastroenterology       Date:  2004-05       Impact factor: 22.682

Review 6.  Revisiting the role of tumor necrosis factor alpha and the response to surgical injury and inflammation.

Authors:  R Ksontini; S L MacKay; L L Moldawer
Journal:  Arch Surg       Date:  1998-05

7.  A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID).

Authors:  J F Colombel; M Lémann; M Cassagnou; Y Bouhnik; B Duclos; J L Dupas; B Notteghem; J Y Mary
Journal:  Am J Gastroenterol       Date:  1999-03       Impact factor: 10.864

8.  Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group.

Authors:  J W Singleton; S B Hanauer; G L Gitnick; M A Peppercorn; M G Robinson; L D Wruble; E L Krawitt
Journal:  Gastroenterology       Date:  1993-05       Impact factor: 22.682

Review 9.  Treatment of luminal and fistulizing Crohn's disease with infliximab.

Authors:  Lawrence W Comerford; Stephen J Bickston
Journal:  Gastroenterol Clin North Am       Date:  2004-06       Impact factor: 3.806

10.  A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.

Authors:  O O Thomsen; A Cortot; D Jewell; J P Wright; T Winter; F T Veloso; M Vatn; T Persson; E Pettersson
Journal:  N Engl J Med       Date:  1998-08-06       Impact factor: 91.245

View more
  1 in total

1.  Novel Rho/MRTF/SRF inhibitors block matrix-stiffness and TGF-β-induced fibrogenesis in human colonic myofibroblasts.

Authors:  Laura A Johnson; Eva S Rodansky; Andrew J Haak; Scott D Larsen; Richard R Neubig; Peter D R Higgins
Journal:  Inflamm Bowel Dis       Date:  2014-01       Impact factor: 5.325

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.